From disease heterogeneity to precision therapy in type 1 diabetes mellitus.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing disease mechanisms and therapeutic strategies without primary data or systematic review methodology.
PubMed 42081016 · doi:10.1007/s12020-026-04637-0
What was done
This narrative review summarizes the etiopathogenic heterogeneity of type 1 diabetes mellitus (T1DM), evaluates emerging therapeutic strategies (including targeted immunotherapies like teplizumab, cytokine inhibitors, tolerance induction, and beta-cell protective agents), and discusses the implementation of candidate stratification biomarkers (such as circulating microRNAs) alongside population-based autoantibody screening.
What was found
The abstract reports no quantitative findings or numerical data. It notes that while agents such as teplizumab represent progress, no curative or durable remission-inducing therapy is currently available, highlighting the need for stage-specific precision therapies and novel circulating biomarkers.
Why it matters
It outlines a framework for transitioning from broad immunosuppression to individualized, stage-specific interventions in type 1 diabetes based on molecular and clinical heterogeneity.
Limits
The abstract provides no empirical data, sample sizes, or systematic review synthesis. Specific diagnostic accuracy, therapeutic effect sizes, and clinical validation metrics for the proposed biomarkers are not detailed.